Doç. Dr. GÜLDANE CENGİZ SEVAL

Yayın Ağı

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

Musto P., Salmanton-García J., Sgherza N., Bergantim R., Farina F., Glenthøj A., et al.

Hematological Oncology , cilt.42, sa.1, 2024 (SCI-Expanded)

Safety of ovarian cryopreservation and transplantation in patients with acute leukemia: a case series

SÖNMEZER M., ŞÜKÜR Y. E., Saçıntı K. G., Özkavukçu S., ENNELİ D., ATABEKOĞLU C. S., et al.

American Journal of Obstetrics and Gynecology , cilt.230, sa.1, 2024 (SCI-Expanded)

The world apheresis association registry, 2023 update

Vrielink H., Le Poole K., Stegmayr B., Kielstein J., Berlin G., Ilhan O., et al.

Transfusion and Apheresis Science , cilt.62, sa.6, 2023 (SCI-Expanded)

Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings.

Rossi G., Salmanton-García J., Cattaneo C., Marchesi F., Dávila-Valls J., Martín-Pérez S., et al.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases , cilt.137, ss.98-110, 2023 (SCI-Expanded)

Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis

Çubukçu H. C., Mesutoğlu P. Y., Seval G., Beksaç M.

CLINICAL AND EXPERIMENTAL MEDICINE , cilt.23, sa.6, ss.2503-2533, 2023 (SCI-Expanded)

Bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation single center experience

IŞIK Ö., CENGİZ SEVAL G., EROL S., GÜRÜN KAYA A., TOPRAK S. K., ÖZDEMİR KUMBASAR Ö.

EUROPEAN RESPIRATORY JOURNAL , 2023 (SCI-Expanded)

Validation of two international myeloma staging systems: second revision of ISS and mayo additive staging sytems (MASS) in an external cohort of Ankara University

CENGİZ SEVAL G., Aydogan M., Akbulut M. H., KARAKAYA B., Yavuz G., YİLMAZ H., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023 (SCI-Expanded)

Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma

CENGİZ SEVAL G., DALVA K., Bakanay S. M., Soydan E., İLHAN O., BEKSAÇ M., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023 (SCI-Expanded)

The Many Faces of Multiple Myeloma (MM).

Bol A. T., Cengiz Seval G., Beksaç M., Kuzu I.

Turkish journal of haematology : official journal of Turkish Society of Haematology , 2023 (SCI-Expanded)

Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center

CENGİZ SEVAL G., Civriz Bozdag S., TOPRAK S. K., Kurt Yuksel M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Balkan medical journal , cilt.40, sa.3, ss.197-204, 2023 (SCI-Expanded)

A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset

BEKSAÇ M., Akin H. Y., CENGİZ SEVAL G., Yurdakul Mesutoglu P., Anliacik R. G., Anliacik E., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.23, sa.5, ss.394, 2023 (SCI-Expanded)

Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.

BEKSAÇ M., Seval G., KOYUN D., TOPÇUOĞLU P., YÜKSEL M., GÜRMAN G., et al.

Clinical lymphoma, myeloma & leukemia , cilt.23, sa.3, 2023 (SCI-Expanded)

Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.

Busca A., Salmanton-García J., Marchesi F., Farina F., Seval G., Van Doesum J., et al.

Frontiers in immunology , cilt.14, ss.1125030, 2023 (SCI-Expanded)

Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

Kırcalı E., Cengiz Seval G., Öztürk C., Yılmaz H., Koyun D., Civriz Bozdağ S., et al.

BALKAN MEDICAL JOURNAL , cilt.40, sa.1, ss.51-56, 2023 (SCI-Expanded)

Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

Ilhan O., Yavuz G., CENGİZ SEVAL G., Bozdag S. C., Yuksel M. K., Topcuoglu P., et al.

BONE MARROW TRANSPLANTATION , cilt.57, sa.SUPPL 1, ss.125, 2022 (SCI-Expanded)

Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

Kircali E., CENGİZ SEVAL G., Bozdag S. C., Yuksel M. K., Topcuoglu P., Arslan O., et al.

BONE MARROW TRANSPLANTATION , cilt.57, sa.SUPPL 1, ss.206-207, 2022 (SCI-Expanded)

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Infante M. S., Salmanton-Garcia J., Fernandez-Cruz A., Marchesi F., Jaksic O., Weinbergerova B., et al.

FRONTIERS IN ONCOLOGY , cilt.12, 2022 (SCI-Expanded)

Late-onset noninfectious pulmonary complications after allogeneic hematopoietic stem cell transplantation- risk factors, prognosis

Isik O., CENGİZ SEVAL G., Erol S., TOPRAK S. K., ÖZDEMİR KUMBASAR Ö.

EUROPEAN RESPIRATORY JOURNAL , 2022 (SCI-Expanded)

Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia

Ozdemir Z. N., Kircali E., Şahin U., Seval G., Bozdağ S. C., Toprak S. K., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.22, sa.8, ss.596-600, 2022 (SCI-Expanded)

COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Lamure S., Salmanton-Garcia J., Robin-Marieton E., Jaksic O., Kohn M., Marchesi F., et al.

BLOOD ADVANCES , cilt.6, sa.13, ss.3870-3874, 2022 (SCI-Expanded)

Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease

KOYUN D., CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , cilt.38, sa.3, ss.601-605, 2022 (SCI-Expanded)

Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association

Joris M. M., Schmidt A. H., Bernas S. N., Feinberg J., Sacchi N., Elmoazzen H., et al.

BONE MARROW TRANSPLANTATION , cilt.57, sa.6, ss.1021-1024, 2022 (SCI-Expanded)

Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome

CENGİZ SEVAL G., Sahin U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAY B. N., et al.

Dermatologic Therapy , cilt.35, sa.5, 2022 (SCI-Expanded)

A case report of an atypical FIP1L1-PDGFRA fusion in a patient with hypereosinophilia

EKİNCİ S., CENGİZ SEVAL G., KARABULUT H. G., Vicdan A., YÜKSEL S., KUZU I., et al.

EUROPEAN JOURNAL OF HUMAN GENETICS , cilt.30, sa.SUPPL 1, ss.222, 2022 (SCI-Expanded)

Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?

CENGİZ SEVAL G., BEKSAÇ M.

FRONTIERS IN ONCOLOGY , cilt.12, 2022 (SCI-Expanded)

SARS-CoV-2 Mutations and their Viral Variants

Cosar B., Karagulleoglu Z. Y., Unal S., Ince A. T., Uncuoglu D. B., Tuncer G., et al.

CYTOKINE & GROWTH FACTOR REVIEWS , cilt.63, ss.10-22, 2022 (SCI-Expanded)

Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Civriz Bozdağ S., Cengiz Seval G., Yönal Hindilerden İ., Hindilerden F., Andıç N., Baydar M., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.39, sa.1, ss.43-54, 2022 (SCI-Expanded)

A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity

BEKSAÇ M., Akin H. Y., Gencer-Oncul E. B., Yousefzadeh M., CENGİZ SEVAL G., GÜLTEN E., et al.

Immunogenetics , cilt.73, sa.6, ss.449-458, 2021 (SCI-Expanded)

Post-Induction Undetectable Minimal Residual Disease at 10 (-5) Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Seval G., DALVA K., Oz D., Bakanay S. M., Soydan E., GÜRMAN G., et al.

BLOOD , cilt.138, 2021 (SCI-Expanded)

The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Ilhan O., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., et al.

BLOOD , cilt.138, 2021 (SCI-Expanded)

Comparison of Salvage Autologous Hematopoietic Cell Transplantation with Outcomes Following Selinexor Combinations Among Double/Triple Refractory Myeloma Patients

Cengiz G., Karakaya B., Yilmaz H., Koyun D., Kircali E., Basboga S., et al.

BLOOD , cilt.138, 2021 (SCI-Expanded)

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Pagano L., Salmanton-Garcia J., Marchesi F., Busca A., Corradini P., Hoenigl M., et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY , cilt.14, sa.1, 2021 (SCI-Expanded)

Analysis of extracorporeal photopheresis within the frame of the WAA register

Blaha M., Berlin G., Audzijoniene J., Griskevicius A., Dykes J., Bhuiyanova Z., et al.

Transfusion and Apheresis Science , cilt.60, sa.5, 2021 (SCI-Expanded)

Rosai-Dorfman disease presenting with nasal, nodal and multiple cutaneous involvements responding to a combination of systemic steroid and low-dose thalidomide therapy.

Kalay Yildizhan İ., ŞANLI H., AKAY B. N., Erol H. M., KUZU I., Kirmizi A., et al.

Dermatologic therapy , cilt.34, sa.4, 2021 (SCI-Expanded)

Deleterious reproductive effects of nilotinib in mouse model

ÖZKAVUKCU İ. S., KUŞCU N., ADIGÜZEL D., CENGİZ SEVAL G., ÇELİK ÖZENCİ Ç.

REPRODUCTION , cilt.161, sa.3, ss.295-306, 2021 (SCI-Expanded)

Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review

Uslu A., CENGİZ SEVAL G., Merter M., DALVA K., BEKSAÇ M.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.21, sa.3, 2021 (SCI-Expanded)

Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic

CENGİZ SEVAL G., TOPÇUOĞLU P., DEMİRER T.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.51, sa.6, ss.2799-2809, 2021 (SCI-Expanded)

Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors

Ozdemir Z. N., Sahin U., DALVA K., BALTACI M. A., Uslu A., Ozturk C., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.2, ss.111-118, 2021 (SCI-Expanded)

Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy

Ozdemir Z. N., CENGİZ SEVAL G., Sahin U., Uslu A., Gunduz M., CİVRİZ BOZDAĞ S., et al.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , cilt.37, sa.1, ss.67-75, 2021 (SCI-Expanded)

Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience

Yilmaz F., SOYER N., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ÜNAL A., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.3, ss.195-203, 2021 (SCI-Expanded)

A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT

Özkan E., Araz M., Cengiz Seval G., Nak D., Beksaç M.

TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.1, ss.69-71, 2021 (SCI-Expanded)

Host variations in SARS-CoV-2 infection

Altiok D., Savci E. Z., Ozkara B., Alkan K., Namdar D. S., Tuncer G., et al.

TURKISH JOURNAL OF BIOLOGY , cilt.45, sa.4, ss.404-424, 2021 (SCI-Expanded)

A New Hope in the Treatment of steroid-refractory Graft Versus Host Disease (Sr-GVHD) after Allogeneic Hematopoetic Stem Cell Transplantation (AHSCT): Ruxolitinib

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., Deveci B., PEHLİVAN M., Kaynar L., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.329-330, 2020 (SCI-Expanded)

The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation

CENGİZ SEVAL G., Kircali E., BALTACI M. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.204, 2020 (SCI-Expanded)

First Turkey Experience of 11C-Methionine PET in Multiple Myeloma. D

Özkan E., Cengiz Seval G., Araz M., Küçük N. Ö., Beksaç M.

TURKISH JOURNAL OF HAEMATOLOGY , ss.1-3, 2020 (SCI-Expanded)

CD34+Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics

Kucukgode G. E., Ipek S., Yildirim Y., Gozukara M. G., DALVA K., CENGİZ SEVAL G., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.688-689, 2020 (SCI-Expanded)

Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplantation with Eltrombopag

Kircali E., CENGİZ SEVAL G., KOYUN D., Ozturk C., Uslu A., CİVRİZ BOZDAĞ S., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.410-411, 2020 (SCI-Expanded)

Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)

CENGİZ SEVAL G., Ulas E. B., TOPRAK S. K., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.192-193, 2020 (SCI-Expanded)

Flamsa-based High-dose Sequential Conditioning Regimen followed by Allogeneic Hematopoietic Stem Cell Transplantation(ALLO-HSCT): Is It Effective in Patients with Primary Refractory or Relapsed Acute Leukemia?

CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.305-306, 2020 (SCI-Expanded)

Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent

Kircali E., Cengiz G., Çolak S., Gunduz M., Ataca Atilla P., Atilla E., et al.

BLOOD , cilt.136, sa.Supplement 1, ss.13-14, 2020 (SCI-Expanded)

Safety and outcome of allogeneic stem cell transplantation in mycosis fungoides and Sezary syndrome: A seven-year tertiary center analysis.

Toprak S. K., Cengiz Seval G., Atilla E., Civriz Bozdag S., Kurt Yuksel M., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15_suppl, ss.20038, 2020 (SCI-Expanded)

Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.

Demirer T., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15_suppl, ss.19522, 2020 (SCI-Expanded)

A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm.

Özcan M., Koyun D., Cengiz Seval G., Uslu A., Kırcalı E., Ozturk C., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15_suppl, ss.19536, 2020 (SCI-Expanded)

First Experience of C-11-Methionine PET in Multiple Myeloma in Turkey

Ozkan E., Cengiz Seval G., Araz M., Kucuk N. Ö., Beksaç M.

TURKISH JOURNAL OF HEMATOLOGY , cilt.39, sa.1, ss.66-67, 2020 (SCI-Expanded)

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome

BEKSAÇ M., CENGİZ SEVAL G., Kanellias N., Coriu D., Rosinol L., Ozet G., et al.

HAEMATOLOGICA , cilt.105, sa.1, ss.201-208, 2020 (SCI-Expanded)

A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R)

BEKSAÇ M., CENGİZ SEVAL G., KOYUN D., TOPÇUOĞLU P., YÜKSEL M., GÜRMAN G., et al.

AMERICAN JOURNAL OF HEMATOLOGY , cilt.94, 2019 (SCI-Expanded)

Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.19, sa.10, 2019 (SCI-Expanded)

Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., Tuglular T. F., ARSLAN Ö., GÖKER H., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.19, sa.10, 2019 (SCI-Expanded)

A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma

CENGİZ SEVAL G., BEKSAÇ M.

EXPERT OPINION ON DRUG SAFETY , cilt.18, sa.7, ss.563-571, 2019 (SCI-Expanded)

THE EFFECT OF PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES PRESENTED BY HLA-CLASS II MOLECULES ON 1 ANTIGEN/ALELLE MISMATCHED UNRELATED HSCT: A SINGLE CENTER EXPERIENCE

DALVA K., CENGİZ SEVAL G., Oz D., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

HLA , cilt.93, sa.5, ss.368-369, 2019 (SCI-Expanded)

Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Ilhan O., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.37, sa.15_suppl, ss.19524, 2019 (SCI-Expanded)

Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

Demirer T., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.37, sa.15_suppl, ss.19532, 2019 (SCI-Expanded)

Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation

Atilla E., Atilla P. A., CENGİZ SEVAL G., Bektas M., DEMİRER T.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.2, ss.122-131, 2019 (SCI-Expanded)

Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience

Gorgulu B., CENGİZ SEVAL G., Kendirlinan R., TOPRAK S. K., Ozcan M., BAVBEK S.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY , cilt.29, sa.6, ss.468-470, 2019 (SCI-Expanded)

Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

Topcuoglu P., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Dalva K., et al.

BLOOD , cilt.132, sa.Supplement 1, ss.5776, 2018 (SCI-Expanded)

Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients

CENGİZ SEVAL G., Sahin D. G., Soydan E. A., Ozcelik T., Gokmen A., Gokgoz Z., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.18, 2018 (SCI-Expanded)

Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience.

CENGİZ SEVAL G., Bulat B., Ozel F., Tasci O., KUZU I., CİVRİZ BOZDAĞ S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded)

Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation

CENGİZ SEVAL G., TOPÇUOĞLU P., DEMİRER T.

BALKAN MEDICAL JOURNAL , cilt.35, sa.2, ss.131-140, 2018 (SCI-Expanded)

The safety of bortezomib for the treatment of multiple myeloma

CENGİZ SEVAL G., BEKSAÇ M.

EXPERT OPINION ON DRUG SAFETY , cilt.17, sa.9, ss.953-962, 2018 (SCI-Expanded)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model

CENGİZ SEVAL G., ÖZKAVUKCU İ. S., SEVAL M. M., Ayli M.

TURKISH JOURNAL OF HEMATOLOGY , cilt.34, sa.2, ss.137-142, 2017 (SCI-Expanded)

Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients

CENGİZ SEVAL G., ÖZCAN M.

JOURNAL OF CLINICAL MEDICINE , cilt.4, sa.3, ss.441-459, 2015 (SCI-Expanded)

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report

Ayh M., ÖZCAN M., CENGİZ SEVAL G.

TURKISH JOURNAL OF HEMATOLOGY , cilt.32, sa.2, ss.180-183, 2015 (SCI-Expanded)

The Effect of Nilotinib in Chronic Myeloid Leukemia Treatment Dose on Spermatogenesis and Folliculogenesis in a Healthy Mouse Model

Seval G., Ozkavukcu S., Seval M., Ayli M., Ozcan M.

BLOOD , cilt.124, sa.21, ss.1799, 2014 (SCI-Expanded)

Blood donors and factors impacting the blood donation decision: Motives for donating blood in Turkish sample

Karacan E., CENGİZ SEVAL G., Aktan Z., Ayli M., Palabiyikoglu R.

TRANSFUSION AND APHERESIS SCIENCE , cilt.49, sa.3, ss.468-473, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

Sirolimus based immunosuppression is associated with need for early repeat therapeutic ERCP in liver transplant patients with anastomotic biliary stricture

Tabibian J. H., Girotra M., Yeh H., Segev D. L., Gulsen M. T., Cengiz-Seval G., et al.

ANNALS OF HEPATOLOGY , cilt.12, sa.4, ss.395-401, 2013 (SCI-Expanded)

HTK preservative solution is associated with increased biliary complications among patients receiving DCD liver transplants: A single center experience

Gulsen M. T., Girotra M., CENGİZ SEVAL G., Price J., Singh V. K., Segev D. L., et al.

ANNALS OF TRANSPLANTATION , cilt.18, ss.69-75, 2013 (SCI-Expanded)

Sirolimus may be associated with early recurrence of biliary obstruction in liver transplant patients undergoing endoscopic stenting of biliary strictures

Tabibian J. H., Yeh H., Singh V. K., CENGİZ SEVAL G., Cameron A. M., Gurakar A.

ANNALS OF HEPATOLOGY , cilt.10, sa.3, ss.270-276, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

Lymphoproliferative Disorders in Individuals With Chronic Hepatitis B and C in the Turkish Population

İDİLMAN R., Bozkus Y., CENGİZ SEVAL G., Mizrak D., ÇINAR K., Ustun Y., et al.

JOURNAL OF MEDICAL VIROLOGY , cilt.83, sa.6, ss.974-980, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.301-302

THE OUTCOME OF SECONDARY AML PATIENTS WITH PRIOR BREAST CANCER UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION IS AS GOOD AS DE NOVO AML

Aydogan M., Karakaya B., Ermis G. Y., Cengiz Seval G., Bozdag S. C., Toprak S. K., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.181-182

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

Karakaya B., Yilmaz H., Ermis G. Y., Cengiz Seval G., Bozdag S. C., Toprak S. K., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.457-458

KRONİK LENFOSİTİK LÖSEMİLERDE İMMUNGLOBULİN GENLERİ VARYANT ALT TİPLERİ, ALT KLONLAR İLE SOMATİK HİPERMUTASYON İLE HASTALIK BİYOLOJİSİNİN İLİŞKİSİ

Aygün R. Ş., Yüksel S., Örüncü M. B., Yüksel M., Cengiz Seval G., Arslan Ö., et al.

49. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 1 - 05 Kasım 2023, ss.148-149

EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

Beksaç M., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians, Paris, Fransa, 23 Nisan 2023, cilt.58, ss.107

Comparison of C-11 methionine and F-18 FDG PET/CT findings in evaluation of multiple myeloma: first Turkey Experience

ÖZKAN E., DEMİR B., CENGİZ SEVAL G., ARAZ M., SOYDAL Ç., BEKSAÇ M., et al.

Annuals Congress of the European Association of Nuclear Medicine, 9 - 13 Eylül 2023

ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND/OR REFRACTORY HODGKIN LYMPHOMA:A MULTICENTER REAL WORLD EXPERIENCE

Koyun D., Şahin U., Cengiz Seval G., Gören Şahin D., Civriz Bozdağ S., Koçak Toprak S., et al.

9th International Congress on Leukemia Lymphoma Myeloma, Antalya, Türkiye, 12 - 13 Mayıs 2023, ss.40-41

Multiple myelomada hastalık değerlendirilmesinde C-11 Metiyonin PET/BT deneyimi

ÖZKAN E., DEMİR B., CENGİZ SEVAL G., ARAZ M., SOYDAL Ç., BEKSAÇ M., et al.

35.Ulusal Nükleer Tıp Kongresi, 26 Nisan 2023

COVID-19 ENFEKSİYONUNUN OTOLOG KÖK HÜCRE NAKLİ UYGULANAN MULTİPLE MYELOM TANILI BİR OLGUDA ETKİSİ

Koyun D., Cengiz Seval G., Civriz Bozdağ S., Özcan M., Beksaç M., Koçak Toprak S.

15. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi , Antalya, Türkiye, 16 - 19 Mart 2023, ss.101

INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE

YILMAZ H., Şahin Y. I., Mammadli H., YILDIZ B., Duran O. F., AYDIN R. F., et al.

9th International Congress on Leukemia Lymphoma Myeloma, Türkiye, 12 Mayıs 2023

THE LDH LEVEL AFTER THE INFUSION OF FRESH OR CRYOPRESERVED HEMATOPOIETIC PROGENITOR CELLS HAVE NO IMPACT ON THE OUTCOME

Sönmez G. M., Conger N., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., BEKSAÇ M., et al.

9th International Congress on Leukemia Lymphoma Myeloma, Türkiye, 12 Mayıs 2023

Phosphatidylserine (PS) and Tyro3-Axl-Mertk (TAM) Receptor Tyrosine Kinase (RTK) Levels Detection and Exosomes Surface in Chronic Lymphocyctic Leukemia (CLL)

Bay M., Cengiz Seval G., Coşkun Ö., Gürman G., Özsoy Erdaş N.

International Congress of Health Research , Ankara, Türkiye, 8 - 09 Aralık 2022, ss.33-34

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

BEKSAÇ M., TUĞLULAR A. T., GAY F., MİNA R., Katodritou E., ÜNAL A., et al.

64th ASH Annual Meeting & Exposition, Amerika Birleşik Devletleri, 9 - 12 Aralık 2022

NÜKS VE DİRENÇLİ HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: ÇOK MERKEZLİ GERÇEK YAŞAM VERİSİ

Koyun D., Şahin U., Cengiz Seval G., Gören Şahin D., Gökmen A., Civriz Bozdağ S., et al.

48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 1 - 05 Kasım 2022, ss.130-132

The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes

Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, cilt.140, ss.12673-12674

Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Yilmaz H., Cengiz Seval G., Karakaya B., Yavuz G., Aydogan M., Bozdag S. C., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, cilt.140, ss.4369-4370

Relaps/Refrakter Mikozis Fungoides ve Sezary Sendromu Vakalarında Brentiksumab Vedotinin Etkinliği: Tek Merkez Deneyimi

CENGİZ SEVAL G., ŞANLI H., GÜNDÜZ K., CİVRİZ BOZDAĞ S., AKAY B. N., YILDIZHAN İ., et al.

30. Ulusal Dermatoloji Kongresi, Girne, Kıbrıs (Kktc), 18 - 22 Ekim 2022

IS IT SAFE TO PERFORM OVARIAN CRYOPRESERVATION AND TRANSPLANTATION IN PATIENTS WITH LEUKEMIA A 5-YEAR SURVIVAL ANALYSIS DATA

Sönmezer M., Şükür Y. E., Saeinti K. G., Ozkavukcu S., Kankaya D., Cengiz Seval G., et al.

78th Annual Scientific Congress and Expo of the American-Society-for-Reproductive-Medicine (ASRM), California, Amerika Birleşik Devletleri, 22 - 26 Ekim 2022

Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable

CENGİZ SEVAL G., KUZU I., Yüksel S., YILMAZ H., Yavuz G., KAYGUSUZ G., et al.

19th International Myeloma Society Annual Meeting, 25 Ağustos 2022

Ibrutınıb As A Promısıng Treatment For Waldenström Macroglobulınemıa

İLHAN O., CENGİZ SEVAL G., AVCU F., Ferhanoglu B., ÖZCAN M., ÇETİN G., et al.

HemaSphere 2022, Amerika Birleşik Devletleri, 05 Haziran 2022

The efficacy and safety of second allogeneic hematopoietic stem cell transplantation

TOPRAK S. K., KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

2022 ASCO Annual Meeting, Amerika Birleşik Devletleri, 01 Haziran 2022

Response And Vaccınatıon Status Or Lack Of Immunoparesıs Are Assocıated Wıth Better Outcome Followıng Covıd-19 Infectıon Among Patıents Dıagnosed Wıth Multıple Myeloma: A Sıngle Center Experıence On 110 Patıents

CENGİZ SEVAL G., KIRCALİ E., KOYUN D., KARAKAYA B., YILMAZ H., AKBULUT H., et al.

3rd European Myeloma Network Meeting Virtual, Amerika Birleşik Devletleri, 06 Nisan 2022

Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

İLHAN O., YAVUZ G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Amerika Birleşik Devletleri, 19 - 22 Mart 2022

Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Amerika Birleşik Devletleri, 19 - 22 Mart 2022

QUANTIFICATION OF MRD AT 10-5 BY FLOW IN THE STEM CELL GRAFT CORRELATES WITH MARROW MRD AND PFS FOLLOWING AHCT AMONG PATIENTS DIAGNOSED WITH MM

CENGİZ SEVAL G., DALVA K., ÖZ M. D., GÜRMAN G., İLHAN O., BEKSAÇ M.

48th Annual Meeting of the EBMT, 19 Mart 2022

İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022

ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI NÜKS ETMİŞ AML HASTALARINDA HİPOMETİLE EDİCİ İLAÇLARLA KOMBİNE VENETOKLAX TEDAVİSİ

ÖZTÜRK C., URAL A. U., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022

GRAFT VERSUS HOST HASTALIĞI PROFİLAKSİSİNDE ATG VE POST CY KULLANIMININ NAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ

Karakaya B., ŞAHİN Y. İ., MAMMADLI H., Yavuz G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022

THE OUTCOME OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN LYPHOMA

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

63TH ASH CONGRESS, ATLANTA, Amerika Birleşik Devletleri, 8 - 11 Aralık 2021

The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

63rd ASH Annual Meeting and Exposition, 11 Aralık 2021

Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic

BEKSAÇ M., TUĞLULAR T., ÜNAL A., Cavo M., Gay F., KATODRITOU E., et al.

63rd ASH Annual Meeting and Exposition, Amerika Birleşik Devletleri, 11 - 13 Aralık 2021

Post-Induction Undetectable Minimal Residual Disease at 10-5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

CENGİZ SEVAL G., DALVA K., ÖZ D., BAKANAY S., SOYDAN E., GÜRMAN G., et al.

63rd ASH Annual Meeting and Exposition, Amerika Birleşik Devletleri, 11 Aralık 2021

Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association

Jöris M., Bernas S., H. Schmidt A., Feinberg J., Sacchi N., Elmoazzen H., et al.

63rd ASH Annual Meeting and Exposition, 11 Aralık 2021

PROFLAKTİK DEFİBROTİD SOS DIŞINDA AKUT GRAFT VS HOST HASTALIĞINDA DA ETKİN

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.

47. Ulusal Hematoloji Kongresi, 04 Kasım 2021

Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation

CENGİZ SEVAL G., DALVA K., ÖZ M. D., ÖZTÜRK S., SOYDAN E., GÜRMAN G., et al.

18th International Myeloma Workshop, Amerika Birleşik Devletleri, 8 - 11 Eylül 2021

Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset

AKIN H., CENGİZ SEVAL G., ATİLLA P., YURDAKUL MESUTOĞLU P., TANER O., ALNIAÇIK R., et al.

18th International Myeloma Workshop, Amerika Birleşik Devletleri, 8 - 11 Eylül 2021

A prospective analysis on the frequency and predictive value of minimal residual disease assessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance

BEKSAÇ M., CENGİZ SEVAL G., ŞAHİN U., MERTER M., İPEK Ş., ÖZKAN E., et al.

23rd Congress of the European Hematology Association, 2021, 14 Haziran 2018, ss.249

DETERMINATION OF INFECTION FREQUENCY IN PATIENTS USING RUXOLITINIB DUE TO GRAFT VERSUS HOST DISEASE

YİLMAZ H., KIRCALI E., ÖZTÜRK C., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

8th International Congress on Leukemia Lymphoma Myeloma, Türkiye, 21 - 22 Mayıs 2021

Postinduction FDG-PET imaging improves the impact of biochemical response assessment on transplant outcome.

Cengiz Seval G., Özkan E., Araz M., Kırcalı E., Koyun D., Gürman G., et al.

8th International Congress on Leukemia Lymphoma Myeloma, 2021, İstanbul, Türkiye, 21 Mayıs 2021, cilt.38, ss.45

Killer Immunoglobulin-like Haplotype BB is Observed More Frequently Among Myeloma Cases Compared to Healthy Controls

AKIN H. Y., ATACA ATİLLA P., YURDAKUL MESUTOĞLU P., CENGİZ SEVAL G., OTLU T., ALNIAÇIK R., et al.

8th International Congress Leukemia Lymphoma Myeloma (ICLLM), 21 - 22 Mayıs 2021

MELFELAN HAZIRLIK REJİMİ TEK GÜN VE İKİ GÜN KULLANIMI YAN ETKİ DEĞERLENDİRMESİ, FARK VAR MI ?

ÖZTÜRK N., BEKLER İ., ERDEMSOY B., ŞEN T., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021

COVID-19 PANDEMİSİNDE ALLOJENEİK HEMATOPOETİK HÜCRELERİN KRİYOPREZERVASYONU

KIRCALI E., ÖZTÜRK C., YILMAZ H., YILDIRIM Y., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021

MELFALAN JENERİKLERİ ARASINDAKİ TİFİLİT YAN ETKİ SIKLIĞININ KARŞILAŞTIRILMASI

ÖZTÜRK N., YILMAZ H., ALKAN TEKEŞ İ., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021

KAN GRUBU UYUŞUMSUZLUĞUNUN HAPLOİDENTİK TRANSPLANT SONUÇLARINA ETKİSİ VE KAN GRUBU DÖNÜŞÜM SÜRECİ

GÖKGÖZ M., ŞAHİN U., GÖKMEN A., SOYDAN E., CENGİZ SEVAL G., ARSLAN Ö., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021

MULTİPL MİYELOMDA OTOLOG PRİFERİK KÖK HÜCRE NAKLİ SONRASI ERKEN NÜKSÜ BELİRLEMEDE CIBMTR, ISS VE R-ISS SKORLAMA SİSTEMLERİNİN KARŞILAŞTIRILMASI

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021

ALLOJENİK KÖK HÜCRE NAKLİ HASTALARINDA PERİTRANSPLANT METRONİDAZOL KULLANIMIYLA AKUT GVHD RİSKİNİN İLİŞKİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021

Yurt İçi Ve Yurt Dışı Gönüllü Akaraba Dışı Vericilerde HLA Özdeşlik Durumu : 10/10 >9/10 Mu Yoksa En Büyük HLADPB1 Mi?

YÜKSEL M., CENGİZ SEVAL G., DALVA K., CEYLAN G., AKAL F., CİVRİZ BOZDAĞ S., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021

PATIENT RELATED FACTORS OVERRIDE LENALIDOMIDE MAINTENANCE AS A FACTOR OF SEVERITY FOR COVID-19 INFECTION

KIRCALI E., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, ss.50 Sürdürülebilir Kalkınma

PRIMARY GASTRIC NK/T CELL LYMPHOMA WITH T CELL PHENOTYPE: A RARE EBV RELATED LOCALLY INVOLVED AGRESSIVE LYMPHOMA CASE.

KOYUN D., YÜKSEL S., CENGİZ SEVAL G., KUZU I., ÖZCAN M., CİVRİZ BOZDAĞ S.

8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.28, ss.60-61

THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., Yavuz G., et al.

8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, sa.71, ss.1-81

Phenotypes of Boone Marrow Monocytes in Stem Cell Transplantatio for acute leukemia: A descriptive pilot study

YÜKSEL M., KIRCALI E., ÖZTÜRK C., YİLMAZ H., KOYUN D., ŞENAY İ., et al.

8th International Congress on Leukemia Lymphoma Myeloma, Türkiye, 21 Mayıs 2021

The impact of pretransplant ımmunomodulatory drugs on cmv reactıvatıon

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., et al.

8th International congress on leukemia lymphoma myeloma, 2021, 21 Mayıs 2021

Is It Safe to Continue Allogeneic Hematopoietic Cell Transplantation Via Cryopreservation during COVID-19 Pandemic?

KIRCALI E., Yavuz G., ÖZTÜRK C., YILMAZ H., CENGİZ SEVAL G., YILDIRIM Y., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR 2021, 08 Şubat 2021

Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent

KIRCALI E., CENGİZ SEVAL G., ÇOLAK S., GÜNDÜZ M., ATACA ATİLLA P., ATİLLA E., et al.

62nd ASH Annual Meeting and Exposition, 05 Aralık 2020

Case Presentation

CENGİZ SEVAL G.

Symposium on Multiple Myeloma and other plasma cell neoplasms, 26 - 28 Kasım 2020

Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data

CENGİZ SEVAL G., İLHAN O., FERHANOĞLU A. B., ÇETİN G., KURTOĞLU E., ATALAY F., et al.

62th ASH Annual Meeting, Amerika Birleşik Devletleri, 2 - 11 Aralık 2020

KÖK HÜCRE ÜRÜNÜNDEKİ CD34 HÜCRE ALT GRUPLARI VE ENGRAFMAN İLE İLİŞKİSİ

CENGİZ SEVAL G., TOPÇUOĞLU P., DALVA K., İLHAN O., YÜKSEL M., CİVRİZ BOZDAĞ S., et al.

46. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020

AKUT MYELOBLASTİK LÖSEMİ HASTALARINDA NÜKLEOFOSMİN MUTASYONU MİNİMAL REZİDÜEL HASTALIK TAKİBİNDE YOL GÖSTERİCİMİDİR

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

42.Ulusal Hematoloji Kongresi, Türkiye, 28 - 30 Ekim 2020

R/ R MULTİPL MYELOM HASTALARINDA BENDAMUSTİN ETKİSİNİN GERİYE YÖNELİK DEĞERLENDİRİLMESİ VE MELFLUFENLE KIYASI

CENGİZ SEVAL G., ÖZCAN M., BEKSAÇ M., ATİLLA E., ATACA ATİLLA P.

42.Ulusal Hematoloji Kongresi, Türkiye, 28 - 30 Ekim 2020

Hematolojik Hastalıklarda Covıd-19 Sıklığı ve Seyri-Çok Merkezli Kayıt Çalışması

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., BEKSAÇ M., TOPÇUOĞLU P., YÜKSEL M.

46.Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020

Foliküler lenfomada bazal PET'te toplam metabolik tümör hacmi ve toplan lezyon glikolizinin prognostik önemi.

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., ÖZKAN E., et al.

46. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020

MM HASTALARINDA TANI SIRASINDA, TEDAVİ SONRASINDA IL-10, VEGF DÜZEYLERİ VE KEMİK İLİĞİNDEKİ PARAMETRELERLE İLİŞKİSİ

CENGİZ SEVAL G., DALVA K., TOPRAK S. K., MEMİŞ F.

42. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020

APLASTİK ANEMİ İLE BİRLİKTELİĞİ OLAN VE OLMAYAN PNHHASTALARINDA ALLOJENEİK KÖK HÜCRE NAKLİ DENEYİMİ

YILMAZ A. F., SOYER N., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., ÜNAL A., et al.

46. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020, ss.86

A New Hope in the Treatment of steroid-refractory Graft Versus Host Disease (Sr-GVHD) after Allogeneic Hematopoetic Stem Cell Transplantation (AHSCT): Ruxolitinib

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., DEVECİ B., PEHLİVAN M., KAYNAR L., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 Ağustos 2020

CD34+ Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics

ERTEPE G., İPEK Ş., YILDIRIM Y., GÖZÜKARA M. G., DALVA K., CENGİZ SEVAL G., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 Ağustos 2020

Flamsa-Based Hıgh-Dose Sequentıal Condıtıonıng Regımen Followed By Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allo-Hsct): Is It Effectıveın Patıents Wıth Prımary Refractory Or Relapsed Acute Leukemıa?

CENGİZ SEVAL G., EKİN K., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 Ağustos - 01 Eylül 2020

Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag

KIRCALİ E., CENGİZ SEVAL G., KOYUN D., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 Ağustos - 01 Eylül 2020

The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., KIRCALİ E., BALTACI M. A., TOPÇUOĞLU P., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 Ağustos - 01 Eylül 2020

Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML)

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DALVA K., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT, 29 Ağustos - 01 Eylül 2020

Diagnosis and follow up of myeloma patients

CENGİZ SEVAL G.

International Myeloma Society, 24 - 25 Temmuz 2020

Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies

KUZU I., CENGİZ SEVAL G., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, Milan, İtalya, 11 Mayıs - 13 Şubat 2020, cilt.22, ss.35

A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm

Özcan M., Koyun D., Cengiz Seval G., Uslu A., Kırcali E., Öztürk C., et al.

ASCO 2020, 29 Mayıs - 02 Haziran 2020, cilt.38, sa.15

Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies

KUZU I., CENGİZ SEVAL G., YÜKSEL M., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, 11 - 13 Mayıs 2020

YÜKSEK DOZ MELFALAN SONRASI YANIT DERİNLİĞİ ARTIŞI NÖTROPENİ DERİNLİĞİ İLEDEĞİL AMA TROMBOSİTOPENİ DERİNLİĞİ İLE İLŞKİLİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020

Hematolojik malignitelerde nakil sonrası hematogon değerlerinin prognoza etkisi var mıdır?

CENGİZ SEVAL G., DALVA K., TOPRAK S. K.

12.Ulusal Kemik iliği transplantasyonu ve hücresel tedaviler kongresi, Türkiye, 5 - 07 Mart 2020

AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020

HEMORAJİK SİSTİT İÇİN YARGILANAN SİKLOFOSFAMİD SUÇSUZ BULUNDU: TEK MERKEZ 7 YILLIK DENEYİM

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020

AKRABA DIŞI VERİCİDEN KHN SÜRECİ BİLEŞENLERİNİN NAKİL ZAMANLAMASINA ETKİSİ: NAKİL ZAMANI DAHA ERKENE ÇEKİLEBİLİR Mİ?

CENGİZ SEVAL G., TOPÇUOĞLU P., BEKSAÇ M., YÜKSEL M., GÜRMAN G., DALVA K., et al.

12.Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020

CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020

KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells

Akin H. Y., Turasan E., Kircali E., AKKUŞ E., CENGİZ SEVAL G., Yurdakul-Mesutoglu P., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, Florida, Amerika Birleşik Devletleri, 19 - 23 Şubat 2020, cilt.26

Ibrutinib As a Promising Treatment for Pulmonary Complications Due to Refractory Chronic Graft Versus Host Disease

İLHAN O., CENGİZ SEVAL G., Uzay A., KAYA E., Ozturk Z. N., Deveci B., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, Florida, Amerika Birleşik Devletleri, 19 - 23 Şubat 2020, cilt.26

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow

CENGİZ SEVAL G., USLU A., KIRCALİ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, 19 - 23 Şubat 2020

Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

CENGİZ SEVAL G., ÖZTÜRK N., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR 2020, 19 - 23 Şubat 2020

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

61st ASH Annual Meeting and Exposition, 7 - 10 Aralık 2019

Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

CENGİZ SEVAL G., KUZU I., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134

A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R)

Beksaç M., Cengiz Seval G., Koyun D., Topçuoğlu P., Yüksel M., Gürman G., et al.

AMERICAN JOURNAL OF HEMATOLOGY, 1 - 05 Kasım 2019

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

CENGİZ SEVAL G., Uslu A., Kircali E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134

Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

CENGİZ SEVAL G., Ozturk N., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134

Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Kircali E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134

NGS TUM SECENEKLERİ TUKETMİŞ NUKS VE DİRENCLİ MMHASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADAREHBERLİK EDEBİLİR Mİ?

CENGİZ SEVAL G., KUZU I., YÜKSEL S., DALVA K., ÖZCAN M., BEKSAÇ M.

45. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 02 Kasım 2019

YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 30 Ekim - 02 Kasım 2019

HANGİSİ, ORJİNAL İMATİNİB Mİ JENERİK Mİ KRONİK MYELOİD LÖSEMİDE DAHA ETKİN?

KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

45. Ulusal Hematoloji Kongresi, 31 Ekim 2019

KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL’DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ?

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 30 Ekim - 02 Kasım 2019

IMID/PI İÇEREN TEDAVİLERE DİRENÇLİ MM OLGULARINDA POM/LEN İLE BİRLİKTE ELOTUZUMAB TEDAVİSİ KALICI ≥ÇİKY SAĞLAYABİLİR Mİ?

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., FIRATLI TUĞLULAR T., ARSLAN Ö., GÖKER H., et al.

45. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 30 Ekim 2019, ss.168

Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 52 patients

CENGİZ SEVAL G., Topcuoglu P., Arslan O., GÜRMAN G., Demirer T., Kuzu I., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.441

Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

BEKSAÇ M., CENGİZ SEVAL G., PAYDAŞ S., TUĞLULAR A. T., ARSLAN Ö., GÖKER A. H., et al.

17th International Myeloma Workshop, 12 - 15 Eylül 2019

Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

17th International Myeloma Workshop, 12 - 15 Eylül 2019

Clonal plasma cell detection by high sensitive flow cytometry in aphaeresis product is poor prognostic and not increased by use of plerixafor alone

CENGİZ SEVAL G., Uslu A., DALVA K., Bakanay S. M., Merter M., Sahin U., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.496-497

Is mobilization with chemotherapy effect response in the multiple myeloma?

CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.500

Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions

İLHAN O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.382

Results of a single center experience: An attempt to augment conditioning regimen in first autologous stem cell transplantation

CENGİZ SEVAL G., KOYUN D., Kircali E., TOPRAK S. K., ÖZCAN M., BEKSAÇ M.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.500-501

Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?

YÜKSEL M., CENGİZ SEVAL G., Uslu A., Kircili E., KOYUN D., Ozturk C., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.505-506

Blood group incompatibility in haplo-identical stem cell transplantation: Favor or unfavorable effect on the erythrocyte recovery?

CENGİZ SEVAL G., Uslu A., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.368-369

Can Nelarabıne Rescue The Graft After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon In T-All ?

YÜKSEL M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

24 Congress of the European Hematology Association, 13 - 16 Haziran 2019

Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37

The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence

DALVA K., CENGİZ SEVAL G., OZ d., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

HLA, 01 Mayıs 2019, cilt.93, ss.368-369

Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

DEMİRER T., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37

retrospective analysis of 149 unselected patıents wıth mantle cell lymphoma confırms prognostic relevance of mıpı: sıngle center ecperıence

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

ICLLM 2019, 02 Mayıs 2019

CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION

Yüksel M., Kırcalı E., Cengiz Seval G., Koyun D., Uslu A., Öztürk C., et al.

7th International Congress on Leukemia Lymphoma, İstanbul, Türkiye, 2 - 04 Mayıs 2019

MULTİPL MİYELOMDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: KİME NE ZAMAN?

CENGİZ SEVAL G.

1. Ulusal Miyelom Uzmanlar Sempozyumu, 08 Mart 2019